<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632511</url>
  </required_header>
  <id_info>
    <org_study_id>BC-06939</org_study_id>
    <nct_id>NCT04632511</nct_id>
  </id_info>
  <brief_title>Metabotyping of Overweight and Obese Children</brief_title>
  <acronym>RecSAMP</acronym>
  <official_title>Metabotyping of Overweight and Obese Children Towards Early Detection of Insulin Resistance and Low-grade Inflammation by Means of a Rectal Sampler</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Algemeen Ziekenhuis Maria Middelares</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ Jan Palfijn Gent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ Sint-Lucas Gent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Ghent</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Today's children are increasingly facing metabolic-related health issues, among which the&#xD;
      worldwide prevalence of overweight and obesity is rising at an alarming pace. Childhood&#xD;
      obesity is associated with the early onset of chronic diseases including an emergence of&#xD;
      prediabetes and diabetes mellitus type 2. The decline of insulin sensitivity already years&#xD;
      before puberty, exposes children to long- term complications prior the appearance of clinical&#xD;
      symptoms and time of diagnosis. The shortened life expectancy and large economic burden&#xD;
      imposed underlines the need for the identification of metabotypes at risk at an early stage.&#xD;
      One's genetics, microbial gut composition and every aspect of the environment in which&#xD;
      children are raised have been implicated in diet-related obesity rendering metabolomics a&#xD;
      very powerful tool towards precision medicine. Yet, the excellence of stool in reflecting the&#xD;
      intertwining thereof is completely unexplored for pediatric purposes, whereas blood sampling&#xD;
      causing pain and stress for child and parent only captures a narrow fraction of the&#xD;
      metabolome. As such, rectal sampling using a customised medical swab for optimal gut&#xD;
      metabolome coverage is envisioned. Ambient laser desorption ionisation will be hyphenated to&#xD;
      high-resolution mass spectrometry-based metabolomics to provide a framework for elucidating&#xD;
      predictive and/or prognostic biomarkers for ever-increasing pediatric metabolic diseases such&#xD;
      as obesity and (pre)diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The impetus for this research proposal stems from the ever-increasing metabolic-related&#xD;
      health issues impacting today's children. Particularly, the high prevalence of childhood&#xD;
      obesity accompanied by substantial progression to 'prediabetic state' at teen age and&#xD;
      full-blown DMT2, the most prevailing endocrine disease worldwide, at early adulthood. Several&#xD;
      risk factors for the development of overt DMT2 and crescent atherogenic processes, including&#xD;
      unhealthy lifestyle patterns, decreased physical activity and (subsequent) obesity, that may&#xD;
      be considered markers of metabolic abnormalities, such as insulin resistance, are already&#xD;
      well-established in children with impaired glucose tolerance prior to time of diagnosis&#xD;
      around early adolescence. Moreover, even in individuals with normal glucose tolerance,&#xD;
      insulin resistance has been pointed out a major risk factor and predictor for the development&#xD;
      of DMT2. Conversely, the micro- and macrovascular events do not readily appear until&#xD;
      maturity, thereby predisposing obese children to the development of several long-term&#xD;
      complications urging the quest for diagnostic, prognostic and/or predictive biomarkers for&#xD;
      insulin resistance and related metabolic diseases. Hence, intervening in the pre-pubertal&#xD;
      life stage becomes of paramount importance. As a pivotal component in precision medicine, and&#xD;
      unlike routine measurements that only include a narrow set of blood chemistry analytes,&#xD;
      metabolomics reveals a far more comprehensive metabolic signature. Taken together that DM and&#xD;
      related comorbidities are considered metabolic diseases with a dysregulated lipid metabolism&#xD;
      being a central factor in the pathogenesis, metabolomics (and in particular lipidomics) is of&#xD;
      key importance in this research proposal. Furthermore, given the collision between genes, gut&#xD;
      microbiota and environmental changes preceding the development of DM and, in addition, the&#xD;
      excellence of stool in reflecting the metabolic interactions and outcomes thereof, an&#xD;
      innovative rectal sampler using a medical swab with customized surface tip for optimal gut&#xD;
      metabolome coverage will be used. REIMS significantly reduces time (&lt; 10 s) and workload&#xD;
      (minimal sample preparation), enhancing research output and efficiency. The aim is the early&#xD;
      identification of children who are destined to develop obesity-related chronic diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Obese children, children with overweight and normal-weight children</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic biomarkers</measure>
    <time_frame>1 year</time_frame>
    <description>The elucidation of candidate biomarkers in the early diagnosis of insulin resistance.&#xD;
The study aims to initially discover differences in metabolic fingerprints of normal-weight versus children with extreme overweight/obesity.&#xD;
The metabolic fingerprints (obtained through state-of-the-art metabolomics technology performed on faecal and urine samples as well as ambient mass spectrometry performed on the rectal swabs) will be correlated to diverse parameters currently addressed in the diagnosis of obesity. Such parameters include BMI z-score, sleeping pattern, anthropometric measurements (waist circumference, standing height, etc.) and clinical blood parameters (standard routine ones like cholesterol, uric acid, ALT, etc.).&#xD;
This will enable to include the aforementioned diverse parameters as plausible covariates (e.g. sex, age, ethnicity, sleeping patterns, etc.) in obtaining true clusters/categories of different metabolic profiles according to underlying metabolic abnormalities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictive and prognostic biomarkers</measure>
    <time_frame>3 years</time_frame>
    <description>The elucidation of predictive and prognostic biomarkers of obesity- and insulin resistance-related metabolic diseases like diabetes type 2.&#xD;
The metabolic fingerprints obtained will be categorised, based on the aforementioned parameters, during the follow-up period in order to retrieve markers of predictive and/or prognostic value with respect to the development and/or progression of obesity-related comorbidities.&#xD;
In this regard, centralised serum samples* will be analysed at UZ Brussel at start, after 1 and 2 years of follow-up, only for the patient group (glucose, insulin, CRP, SHBG, adiponectin, leptine and free fatty acids) to correlate the metabolic profiles to metabolic abnormalities (based on those blood measurements) like dyslipidemia, low-grade inflammation, etc.&#xD;
*Those measurements impart 1 extra serum sample taken by the pediatricians during routine practice (so the patients already do need to come in fasting for blood sampling on those days of consultation).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Metabolic Disease</condition>
  <condition>Obesity, Infant</condition>
  <arm_group>
    <arm_group_label>Obese group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Metabolome measurements on feces and urine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children with overweight, not yet obese</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Metabolome measurements on feces and urine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal-weight control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Metabolome measurements on feces and urine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RECSAMP</intervention_name>
    <description>Rectal Sampler</description>
    <arm_group_label>Children with overweight, not yet obese</arm_group_label>
    <arm_group_label>Normal-weight control group</arm_group_label>
    <arm_group_label>Obese group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  prepubertal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no diabetes type 1 or 2, no endocrine disease, no chronic medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean De Schepper</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean De Schepper</last_name>
    <phone>09 332 27 60</phone>
    <email>jean.deschepper@uzbrussel.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ghent University</name>
      <address>
        <city>Ghent</city>
        <state>East-flanders</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Vanhaecke, Prof.</last_name>
      <phone>0495590750</phone>
      <email>Lynn.Vanhaecke@UGent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylvia Depoorter</name>
      <address>
        <city>Bruges</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Depoorter</last_name>
      <phone>0478248178</phone>
      <email>sylviaa.depoorter@azsintjan.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital Jan-Palfijn</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nele Baeck</last_name>
      <phone>09 224 71 11</phone>
      <email>nele.baeck@azjanpalfijn.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital Maria-Middelares</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jelle Degraeuwe</last_name>
      <phone>09 246 46 46</phone>
      <email>jelle.degraeuwe@azmmsj.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital Sint-Lucas</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Deman</last_name>
      <phone>09 224 54 13</phone>
      <email>sofie.deman@azstlucas.be</email>
    </contact>
    <investigator>
      <last_name>Sofie Deman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Brussels</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inge Gies</last_name>
      <phone>023060223</phone>
      <email>inge.gies@uzbrussel.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Casteels</last_name>
      <phone>016343991</phone>
      <email>kristina.casteels@uzleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metabolomics</keyword>
  <keyword>mass spectrometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

